Please assess the completion status of the following clinical trial:

Trial Title: TMS in Inflammatory Bowel Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* confirmed diagnosis of IBD, demonstrated to be in endoscopic remission (Mayo Endoscopic Subscore \[for UC\] 0 or 1, or Simple Endoscopic Score for CD ≤4) or biomarker remission (fecal calprotectin \<250 ug/g) within 6 months of randomization~* ≥8 on the Hospital Anxiety and Depression Scale~* on stable IBD-related and psychotropic medications for the four weeks preceding randomization~Exclusion Criteria:~* severely active IBD (Mayo score \> 9, HBI \> 16)~* require systemic corticosteroids~* initiated biologic treatment within the preceding three months~* suicidal ideation~* psychosis~* having failed ECT~* previous rTMS treatment (for blinding integrity)~* contraindications for MRI~* Use of benzodiazepines or GABA agonists

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active iTBS rTMS (Type: ACTIVE_COMPARATOR): The active arm involves magnetic stimulation of the brain to the left dorsolateral prefrontal cortex (DLPFC) twice daily for two weeks (20 sessions). The active arm will be receiving intermittent Theta-Burst (iTBS) repetitive Transcranial Magnetic Stimulation (rTMS) to deliver magnetic pulses.
- Sham iTBS rTMS (Type: SHAM_COMPARATOR): sham rTMS treatment involves scalp stimulation with no magnetic pulse twice daily for two weeks (20 sessions). Sham rTMS involves only the click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered to the brain.

Based on this trial design, predict the completion outcome and termination type (if applicable).